Orpyx Medical Technologies' Patent: Innovative Solution for Calibrating Force Sensors in Sensorized Insoles
New York, NY - Orpyx Medical Technologies, a frontrunner in healthcare innovation, has recently secured a patent (US20240099419A1) for a system and method that addresses a critical problem faced by users of sensorized insoles. These insoles, designed to provide valuable data about human movement and activity, rely on accurate force measurements to deliver meaningful insights. However, ensuring precise calibration of these force sensors has proved to be a daunting task, leading to inaccuracies and limitations in use.
The core problem lies in the fact that while factory calibration can assure initial accuracy, sensors may drift and lose calibration over time due to changes in external conditions. Additionally, users often find inter-use calibration routines, which require their active participation, inconvenient or cumbersome. As a result, they tend to neglect these calibration routines, compromising the accuracy of their sensorized devices.
Orpyx's newly patented solution completely transforms this scenario by introducing a simple and convenient process for inter-use calibration, eliminating the need for factory calibration altogether. The innovative system employs a force sensing apparatus that not only facilitates calibration but also charges the sensorized device simultaneously. By integrating the calibration routine into the charging process, users are naturally inclined to perform regular calibrations as part of their daily routine.
Unique in its design, the wireless charging unit is exceptionally user-friendly, making it easily accessible to users, even those with limited mobility or dexterity. The device allows for charging without necessitating the removal of the sensorized insole from the shoe, reducing any hassle for the user. Simply placing the shoe on the wireless charging mat initiates the charging process, utilizing an LC (inductor capacitor) circuit for efficient charging. Additionally, a visual indicator is provided, allowing users to visually confirm the ongoing charging process.
The inter-use calibration system implemented by Orpyx resolves two critical issues. Firstly, it eliminates the need for expensive and time-consuming factory recalibrations, significantly reducing manufacturing costs. Secondly, it encourages users to perform calibrations more regularly, ensuring the accuracy of their sensorized insoles with minimal effort.
Moreover, the patent also enables intra-use calibration, ensuring accurate readings even while the device is in use. This feature updates the reference value when changes occur, such as variations in clothing weight. Ultimately, combining inter-use and intra-use calibration ensures consistently precise measurements for users.
Imagine a world where individuals can effortlessly harness the power of sensorized insoles for a diverse range of activities, such as running, walking, jumping, cycling, and even gaming. Orpyx's groundbreaking patent opens up possibilities for improved physical performance, injury prevention, and enhanced overall wellness. Athletes can fine-tune their movements, medical professionals can monitor rehabilitation progress, and individuals can gain valuable insights into their daily activities to optimize their health.
It is crucial to note that, being a patent, the appearance of this innovation in the market is not a certainty. However, if this development becomes accessible, it has the potential to revolutionize the field of sensorized insoles, empowering users with accurate and reliable data.
In times when the demand for precision and personal monitoring is on the rise, Orpyx's patent stands as a promising solution, addressing the challenges surrounding force sensor calibration in sensorized insoles. By simplifying the calibration process and creating a seamless user experience, this patent paves the way for a new era of accurate and accessible data-driven insights.
P.S. Please note that this article is based on a recently published patent, and whether this innovation will be available in the market remains uncertain.